Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation

Experimental Cell Research

Volumn 304, Issue 2, 2005, Pages 604-619

  Diermeier, Simone ^a   Horváth, Gábor ^b   Knuechel Clarke, Ruth ^c   Hofstaedter, Ferdinand ^a   Szöllosi, János ^b   Brockhoff, Gero ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Breast cancer treatment; Cell cycle; EGFR; erbB receptors; FRET; HER2 neu; Herceptin; Proliferation; Receptor interaction

Indexed keywords

BROXURIDINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL LABELING; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

EID: 14644392200     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.12.008     Document Type: Article

References (54)

1. D. Slamon, and M. Pegram Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials Semin. Oncol. 28 2001 13 19
2. M.F. Press, D.J. Slamon, K.J. Flom, J. Park, J.Y. Zhou, and L. Bernstein Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J. Clin. Oncol. 20 2002 3095 3105
3. J.M. Bartlett, J.J. Going, E.A. Mallon, A.D. Watters, J.R. Reeves, P. Stanton, J. Richmond, B. Donald, R. Ferrier, and T.G. Cooke Evaluating HER2 amplification and overexpression in breast cancer J. Pathol. 195 2001 422 428
4. M.D. Pegram, G. Konecny, and D.J. Slamon The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer Cancer Treat. Res. 103 2000 57 75
5. Y. Tokuda Antibodies as molecular target-based therapy: trastuzumab Int. J. Clin. Oncol. 8 2003 224 229
6. Y. Yarden Biology of HER2 and its importance in breast cancer Oncology 61 2001 1 13
7. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin. Oncol. 26 1999 60 70
8. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev., Mol. Cell Biol. 2 2001 127 137
9. P. Nagy, A. Jenei, S. Damjanovich, T.M. Jovin, and J. Szollosi Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy Pathol. Oncol. Res. 5 1999 255 271
10. P. Nagy, D.J. Arndt-Jovin, and T.M. Jovin Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells Exp. Cell Res. 15 2003 39 49
11. N. Normanno, M. Campiglio, L.A. De, G. Somenzi, M. Maiello, F. Ciardiello, L. Gianni, D.S. Salomon, and S. Menard Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann. Oncol. 13 2002 65 72
12. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
13. M.D. Pegram, G.E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D.J. Slamon Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J. Natl. Cancer Inst. 96 2004 739 749
14. M.D. Pegram, A. Lopez, G. Konecny, and D.J. Slamon Trastuzumab and chemotherapeutics: drug interactions and synergies Semin. Oncol. 27 2000 21 25
15. M.D. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt, M.X. Sliwkowski, D. Coombs, D. Baly, F. Kabbinavar, and D.J. Slamon Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 1999 2241 2251
16. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
17. M.A. Olayioye, R.M. Neve, H.A. Lane, and N.E. Hynes The erbB signaling network: receptor heterodimerization in development and cancer EMBO J. 19 2000 3159 3167
18. M.H. Kraus, N.C. Popescu, S.C. Amsbaugh, and C.R. King Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms EMBO J. 6 1987 605 610
19. G. Brockhoff, P. Heiß, J. Schlegel, F. Hofstaedter, and R. Knuechel Epidermal-Growth-Factor-Receptor, c-erbB2 and c-erbB3 receptor interaction and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells Cytometry 44 2001 338 348
20. P. Nagy, L. Bene, M. Balazs, W.C. Hyun, S.J. Lockett, N.Y. Chiang, F. Waldman, B.G. Feuerstein, S. Damjanovich, and J. Szollosi EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements Cytometry 32 1998 120 131
21. Z. Sebestyen, P. Nagy, G. Horvath, G. Vamosi, R. Debets, J.W. Gratama, D.R. Alexander, and J. Szollosi Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer Cytometry 48 2002 124 135
22. S. Diermeier, E. Schmidt-Bruecken, M. Kubbies, L.A. Kunz-Schughart, and G. Brockhoff Exposure to continuous bromodeoxyuridine (BrdU) differentially affects cell cycle progression of human breast and bladder cancer cell lines Cell Proliferation 37 2004 195 206
23. L. Trón, J. Szöllosi, S. Damjanovich, S.H. Helliwell, D.J. Arndt-Jovin, and T.M. Jovin Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis Biophys. J. 45 1984 939 946
24. L. Trón, J. Szöllosi, S. Damjanovich, S.H. Helliwell, D.J. Arndt-Jovin, and T.M. Jovin Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces, quantitative evaluation of the transfer efficiency on a cell-by-cell basis Biophys. J. 45 1984 939 946
25. G. Szentesi, G. Horváth, I. Bori, G. Vámosi, J. Szöllosi, R. Gáspár, S. Damjanovich, A. Jenei, and L. Mátyus Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis Comput. Methods Programs Biomed. 75 2004 201 211
26. H.A. Lane, I. Beuvink, A.B. Motoyama, J.M. Daly, R.M. Neve, and N.E. Hynes ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency Mol. Cell. Biol. 20 2000 3210 3223
27. L.F. Gulli, K.C. Palmer, Y.Q. Chen, and K.B. Reddy Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity Cell Growth Differ. 7 1996 173 178
28. C.L. MacLeod, A. Luk, J. Castagnola, M. Cronin, and J. Mendelsohn EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells J. Cell. Physiol. 127 1986 175 182
29. J.M. Rae, and M.E. Lippman Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors Breast Cancer Res. Treat. 83 2004 99 107
30. J. Filmus, M.N. Pollak, R. Cailleau, and R.N. Buick MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF Biochem. Biophys. Res. Commun. 30 1985 898 905
31. O. Tikhomirov, and G. Carpenter Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2 J. Biol. Chem. 26 2004 12988 12996
32. K.B. Fallon, N. Havlioglu, L.H. Hamilton, T.P. Cheng, and S.L. Carroll Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line J. Neuro-Oncol. 66 2004 273 284
33. A.B. Motoyama, N.E. Hynes, and H.A. Lane The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res. 1 2002 3151 3158
34. T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas III, and N.E. Hynes The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Proc. Natl. Acad. Sci. 100 2003 8933 8938
35. G.K. Scott, J.M. Dodson, P.-A. Montgomery, R.M. Johnson, J.C. Sarup, W.L. Wong, A. Ullrich, H.M. Shepard, and C.C. Benz p185HER2 signal transduction in breast cancer cells J. Biol. Chem. 5 1991 14300 14305
36. J.C. Sarup, R.M. Johnson, K.L. King, B.M. Fendly, M.T. Lipari, M.A. Napier, A. Ullrich, and H.M. Shepard Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth Growth Regul. 1 1991 72 82
37. L.N. Klapper, H. Waterman, M. Sela, and Y. Yarden Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2 Cancer Res. 1 2000 3384 3388
38. S.A. Ettenberg, A. Magnifico, M. Cuello, M.M. Nau, Y.R. Rubinstein, Y. Yarden, A.M. Weissman, and S. Lipkowitz Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex J. Biol. Chem. 20 2001 27677 27684
39. K. Shtiegman, and Y. Yarden The role of ubiquitylation in signaling by growth factors: implications to cancer Semin. Cancer Biol. 13 2003 29 40
40. J. Albanell, J. Codony, A. Rovira, B. Mellado, and P. Gascon Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4 Adv. Exp. Med. Biol. 532 2003 253 268
41. A. Badache, and N.E. Hynes A new therapeutic antibody masks ErbB2 to its partners Cancer Cells 5 2004 299 301
42. Y. Nagata, K.H. Lan, X. Zhou, M. Tan, F.J. Esteva, A.A. Sahin, K.S. Klos, P. Li, B.P. Monia, N.T. Nguyen, G.N. Hortobagyi, M.C. Hung, and D. Yu PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cells 6 2004 117 127
43. M.D. Marmor, K.B. Skaria, and Y. Yarden Signal transduction and oncogenesis by ErbB/HER receptors Int. J. Radiat. Oncol., Biol., Phys. 1 2004 903 913
44. D.J. Slamon The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors Oncologist 9 2004 1 3
45. M.M. Moasser, A. Basso, S.D. Averbuch, and N. Rosen The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res. 1 2001 7184 7188
46. S.L. Moulder, and C.L. Arteaga A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2) Clin. Breast Cancer 4 2003 142 145
47. S.L. Moulder, F.M. Yakes, S.K. Muthuswamy, R. Bianco, J.F. Simpson, and C.L. Arteaga Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res. 15 2001 8887 8895
48. B.S. Hendriks, L.K. Opresko, H.S. Wiley, and D. Lauffenburger Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects Cancer Res. 63 2003 1130 1137
49. N. Normanno, C. Bianco, A. De Luca, M.R. Maiello, and D.S. Salomon Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment Endocr. Relat. Cancer 10 2003 1 21
50. B.S. Hendriks, L.K. Opresko, H.S. Wiley, and D. Lauffenburger Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects Cancer Res. 63 2003 1130 1137
51. G.E. Konecny, C.A. Wilson, and D.J. Slamon Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? J. Natl. Cancer Inst. 17 2003 1813 1815
52. D. Ye, J. Mendelsohn, and Z. Fan Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 Oncogene 18 1999 731 738
53. S. Tsutsui, S. Ohno, S. Murakami, A. Kataoka, J. Kinoshita, and Y. Hachitanda Prognostic value of the combination of epidermal growth factor receptor and c-erbB2 in breast cancer Surgery 133 2003 219 221
54. Y. Yarden The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities Eur. J. Cancer 37 2001 3 8